Agilent Announces Unique Portfolio to Advance Immunotherapy
May 07 2019 - 08:00AM
Business Wire
Innovative solution provides cell-based tools for translational
research and development
Agilent Technologies Inc. (NYSE: A) announces a unified
portfolio of products for immunotherapy researchers. The innovative
solution will showcase at Immunology 2019, the 103rd Annual Meeting
of the American Association of Immunologists (AAI), taking place in
San Diego, CA on May 9-13, 2019.
“Immunotherapy is changing the landscape of cancer treatment,
but most of the available tools are adapted and not purpose-built
for this cell-centric workflow,” said David Ferrick, Ph.D., senior
director of the Cell Analysis Division at Agilent Technologies.
“This is why we have placed so much emphasis on assembling and
harmonizing innovative cell-based solutions. We want to enable
researchers and developers to overcome the challenges and capture
the opportunities of this rapidly growing field.”
“To find the answers, flow cytometry approaches, kinetic
measures of live-cell metabolism, and quantifying the ability of T
cells to kill targets over time, are all aspects that can be
investigated now with the tools that Agilent provides,” said Carl
June, MD, professor in immunotherapy at the Perelman School of
Medicine at the University of Pennsylvania and Abramson Cancer
Center. “Any cell-based assay that improves the probability that
you’re going to have an effective cell product will be something
that everyone wants.”
Agilent’s new offering includes four purpose-built components
that naturally complement:
- Agilent SureGuide Chemically
Synthesized sgRNAs: Deliver the best guides to enable the full
potential of CRISPR for cellular engineering and
immunotherapy.
- NovoCyte Quanteon Flow
Cytometer: Quickly and accurately immunophenotype with up to
25 channels of fluorescence using the most sensitive silicon
photomultiplier detector technology on the market. Experience the
new standard in flow cytometry.
- xCELLigence RTCA eSight: Capture
dynamic cell behavior and follow the biology that can be missed by
labor-intensive endpoint assays to quantify, in real-time critical
events like cancer cell killing.
- Agilent Seahorse XF Analyzers: Discover
and tune immune cell metabolism to mount a sustained and robust
anti-tumor response. XF analyzers are the market leading choice for
this type of work.
An Agilent workshop titled Breakthroughs in immunotherapy: Tune
the drivers of immune cell potency, fate and persistence, presented
by David Ferrick, will be held on Sunday, May 12, 10:00 - 10:45
a.m. in Room 2 of the San Diego Convention Center, Exhibit Halls F
& G. To learn more, visit the Agilent booth #1315 and the ACEA
(a part of Agilent) booth #1030 at Immunology 2019, or go to
www.agilent.com/en/solutions/cell-metabolism/immune-cell-therapy.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics and applied chemical markets. With more than
50 years of insight and innovation, Agilent instruments, software,
services, solutions, and people provide trusted answers to
customers' most challenging questions. The company generated
revenues of $4.91 billion in fiscal 2018 and employs 15,300 people
worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, subscribe to
our Newsroom. Follow Agilent on LinkedIn, Twitter, and
Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190507005389/en/
Naomi GoumilloutAgilent Technologies,
Inc.+1.781.266.2819naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Feb 2024 to Mar 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2023 to Mar 2024